Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
NCT Number: NCT00656565
Adequate administration of drugs via dry powder inhalers is dependent on adequate inspiratory flow rates and volumes. These vary according to the device being used and its resistance. The dry powder inhaler device under investigation is a device approved by the Therapeutic Goods Administration (ARTG no. 196255) for use with dry powder mannitol. Dry powder mannitol is currently being investigated as a treatment for bronchiectasis. We wish to measure the inspiratory flow characteristics of both the low and high resistance devices amongst a group of subjects with bronchiectasis.
We propose that the majority of subjects investigated with varying lung function will achieve adequate flow during a controlled inspiration.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Camperdown, New South Wales, 2050, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: single visit
Time frame: single visit
Syntara
Industry
Inspiratory Flow Rates and Volumes in Subjects With Bronchiectasis Using Low and High Resistance Dry Powder Inhaler Devices
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05238675
Bronchial Diseases, Bronchiectasis
Peoria, Arizona, United States
View Trial DetailsNCT02804971
Bronchial Diseases, Bronchiectasis
Créteil, France
View Trial DetailsNCT05865886
Bronchial Diseases, Bronchiectasis
Denver, Colorado, United States
View Trial DetailsNCT07063290
Bronchial Diseases, Bronchiectasis
Hangzhou, Zhejiang, China
View Trial Details